QMSR 2026 Explained: FDA Quality Management System Regulation & ISO 13485 Alignment Guide

What is QMSR 2026?

QMSR 2026 is the FDA’s updated Quality Management System Regulation that replaces QSR under 21 CFR Part 820 and aligns U.S. medical device regulations with ISO 13485:2016 to improve global harmonization, inspection transparency, and lifecycle compliance.

Quality Management System Regulation (QMSR) 2026

On 2nd February 2026, the USA Food and Drug Administration (FDA )implemented the Quality Management System Regulation (QMSR) which replaced the previous Quality System Regulation (QSR) under 21 CFR Part 820. This marks one of the most significant regulatory changes for medical device manufacturers in decades.

QMSR aligns U.S. requirements with globally recognized standards like ISO 13485:2016 and ISO 9000:2015 Clause 3. This makes the FDA's framework in line with international standards. By retiring the Quality System Inspection Technique (QSIT) and introducing a new inspection program (Compliance Program 7382.850), the FDA moves towards modernized its approach to ensure consistency, transparency, and accountability throughout the Total Product Life Cycle (TPLC) of medical devices.

This shift is not just about regulatory alignment, it is for exposing vulnerabilities, enhancing risk management, and integrating cybersecurity and quality into every stage of device development and post-market monitoring. For manufacturers QMSR 2026 presents both a challenge to overcome compliance gaps and an opportunity to build resilience, trust and global competitiveness.

Background: From QSR to QMSR

The Quality System Regulation (QSR) under 21 CFR Part 820 was established in the late 1990s, providing a framework for medical device manufacturers in the U.S. It required companies to implement quality systems that ensured devices were consistently designed, manufactured, and distributed to meet safety and efficiency standards. For decades, QSR was the foundation of FDA inspections where the Quality System Inspection Technique (QSIT) guiding compliance assessments.

QSR was U.S.-centric and as global medical device markets expanded, manufacturers often faced duplicative audits and compliance challenges to meeting both FDA requirements and international standards like ISO 13485.

Reason for the FDAs move to harmonize with ISO 13485:2016

To reduce regulatory burdens and promote global consistency, the FDA issued a final rule in January 2024 amending Part 820. The revised regulation which is called the Quality Management System Regulation (QMSR), incorporates ISO 13485:2016 by reference.

ISO 13485 is the internationally recognized standard for medical device quality management systems, adopted by regulators in Europe, Canada, Japan, and many other jurisdictions. By aligning with ISO 13485, the FDA ensures:

Patient Safety & Innovation

This shift reflects the FDA’s commitment in modernizing its regulatory framework, exposing vulnerabilities in outdated systems, and ensuring U.S. oversight remains consistent with global best practices.

Key changes in QMSR 2026

QMSR introduces crucial updates that will determine how medical device manufacturers approach compliance and inspections:

1. Retirement of QSIT

QSIT has been retired. The FDA now uses Compliance Program 7382.850, providing a modernized inspection framework aligned with QMSR requirements.

2. Incorporation of ISO 13485 by Reference

QMSR incorporates ISO 13485:2016 and ISO 9000:2015 Clause 3, ensuring U.S. regulations align with international standards. This will also reduce duplication and will help in maintaining FDA-specific clarifications.

3. Expanded Inspection Authority

QMSR allowances FDA inspecting authority to assess management reviews, internal audits, and supplier audit reports.

4. Clarifications for combination products

Edits to 21 CFR Part 4 clarify how QMS requirements apply to combination products, ensuring consistency across product categories.

5. Lifecycle Accountability

QMSR emphasizes compliance across the TPLC. Risk management, design controls, manufacturing, labelling, distribution, and post-market surveillance are interconnected, highlighting the need for a complete quality control.

What the FDA will examine

Reopened CAPAs: Evidence that problems weren't completely resolved the first time. Repeated reopenings indicate systemic flaws and weaknesses.

Repeat Nonconformances: Repeated issues in audits, complaints, or production records, highlights ineffective corrective actions.

Unresolved Trends: Data showing negative trends such as deviations, complaints, service reports were identified but not addressed.

Leadership Accountability: The FDA will examine whether management evaluated CAPA effectiveness, allocated resources, and acted promptly. The FDA expects operational solutions leadership engagement.

OEM Oversight

QMSR highlights the importance of Original Equipment Manufacturer (OEM) oversight as a primary compliance requirement. The FDA expects manufacturers to maintain continuous, risk-based control over suppliers and outsourced processes.

Supplier evaluation and monitoring – OEMs must assess, select, and monitor suppliers using documented risk-based criteria.
Critical supplier management – Suppliers involved in high-risk areas (such as sterilization, software, and component manufacturing) need more thorough audits, validation evidence, and continuous performance monitoring.
Responsibility – OEMs cannot delegate accountability. The legal manufacturer holds full responsibility for product quality.
Leadership Involvement – Supplier risks should be reported to management review, with documented actions taken.

This is consistent with ISO 13485 clause 7.4 (Purchasing), with added emphasis by the FDA on traceability, CAPA linkage, and executive accountability.

Impact on FDA Inspections

QMSR 2026 changes FDA medical device inspections, modernizing the process and aligning it with international practices. This includes:

1. New Inspection Program (Compliance Program 7382.850)

The updated Compliance Program 7382.850 emphasizes risk management, lifecycle accountability, and alignment with ISO 13485.

2. FDA records and review

FDA inspectors have extended authority to assess management reviews, internal audits, and supplier audit reports, ensuring transparency and consistency.

3. Differences compared to MDSAP audits

While QMSR inspections align with ISO 13485 principles, they focus on compliance with U.S. regulations. MDSAP audits are voluntary and focus on ISO 13485 conformance across multiple authorities.

New subsections in 21 CFR Part 820

The FDA’s Quality Management System Regulation (QMSR 2026) introduces four new subsections in 21 CFR Part 820, aligning U.S. medical device regulations with ISO 13485:2016. These subsections include:

1. § 820.35 – Control of Records

Expands FDA's authority to review records like management reviews, internal audits, and supplier audits.

It ensures transparency and aligns with international inspection practices.

2. § 820.45 – Control of Documents

It requires manufacturers to set up procedures for document approval, distribution, changes and updates.

It emphasizes data management and changes control across the product lifecycle.

3. § 820.65 – Control of Nonconforming Product

It strengthens requirements for identifying, documenting, and addressing nonconforming products.

It aligns with ISO 13485 regulation for corrective and preventive actions.

4. § 820.75 – Validation of Processes

It covers validation requirements for outsourced activities, concurrent validation, and continuous process verification.

Highlights risk management, supplier qualification, and periodic review required for robust process control.

Implications for Medical Device Manufacturers

QMSR 2026 reshapes how medical device companies operate, exposing weaknesses, demanding stronger documentation, and pushing toward global alignment:

1. Exposure of vulnerabilities

QMSR inspections reveal gaps in quality systems. Processes previously shielded are now subject to FDA scrutiny, requiring comprehensive compliance.

2. Documentation and audit readiness

Manufacturers must maintain audit-ready documentation. Records created before February 2, 2026, will be reviewed under QMSR.

3. Cybersecurity Integration

Cybersecurity is now a core quality requirement. Device makers must integrate secure design, vulnerability monitoring, and incident response into their QMS.

4. Global alignment and competitive advantage

By harmonizing with ISO 13485:2016, QMSR reduces duplication, streamlines global compliance, and enhances credibility with regulators and patients.

Preparing for compliance

With QMSR implementation, manufacturers must be prepared by integrating quality, risk management, and cybersecurity throughout product lifecycle.

1. Practical steps for manufacturers

Manufacturer must conduct a gap analysis, update documentation, strengthen supplier quality, and integrate cybersecurity measures.

2. Training, gap analysis, and harmonization strategies

Manufacturer must train staff, perform internal audits, harmonize systems across operations, and prepare inspection readiness plans.

3. Employing ISO 13485 guidance and mapping tools

Use AAMI/ISO 13485:2016 and AAMI TIR102:2019 to ensure no gaps remain and maintain a compliance matrix for audit readiness.

Conclusion:

The implementation of QMSR 2026 marks a significant moment in medical device regulation. By harmonizing with ISO 13485:2016, retiring QSIT, and expanding inspection authority, the FDA emphasizes global alignment, transparency, and lifecycle accountability.

For manufacturers, this is more than a compliance, it’s an opportunity to provide quality throughout the product lifecycle. Implementation of QMSR 2026 will builds trust with patients and regulators. It will help in strengthens resilience, and hence the manufacturer will gain competitive advantages in global markets. In this new fast growing global market quality is now just regulatory requirement it is the foundation of innovation, safety, and long-term success.

Visit Sushvin @ SUSHVIN- Best Quality & Regulatory Experts for Medical Devices in UK for guidance on

Regulatory & Compliance Services

QMSR 2026 Gap Analysis – We at Sushvin provide guidance on existing QSR systems against new QMSR subsections (§820.35, §820.45, §820.65, §820.75) and ISO 13485 alignment.
Audit-Ready Documentation – We help in developing and harmonize SOPs, validation and compliance matrices for FDA and NB inspections.
Inspection Readiness – We provide guidance for manufacturers on FDA’s new Compliance Program 7382.850, including internal audits and record review.
Combination Product Clarifications –We provide guidance on 21 CFR Part 4 updates for combination products under QMSR.